# Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

> **NCT04324112** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (estimated)

## Conditions studied

- Hairy Cell Leukemia

## Interventions

- **DRUG:** binimetinib
- **DRUG:** Encorafenib

## Key facts

- **NCT ID:** NCT04324112
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-28
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-07-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04324112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04324112, "Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04324112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*